Display Settings:

Format

Send to:

Choose Destination
J Neuroimmunol. 2010 Feb 26;219(1-2):105-8. doi: 10.1016/j.jneuroim.2009.11.014. Epub 2009 Dec 6.

High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases.

Author information

  • 1Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Gifu, Japan. kimura1@gifu-u.ac.jp

Abstract

We identified the autoantibody against phosphoglycerate mutase 1 (PGAM1), which is a glycolytic enzyme, in sera from multiple sclerosis (MS) patients by proteomics-based analysis. We further searched this autoantibody in sera from patients with other neurological diseases. The prevalence of the anti-PGAM1 antibody is much higher in patients with MS and neuromyelitis optica (NMO) than in those with other neurological diseases and in healthy controls. It was reported that the anti-PGAM1 antibody is frequently detected in patients with autoimmune hepatitis (AIH). Results of our study suggest that the anti-PGAM1 antibody is not only a marker of AIH but also a nonspecific marker of central nervous system autoimmune diseases.

Copyright 2009 Elsevier B.V. All rights reserved.

PMID:
19969379
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk